Skip to main content

Table 4 Combined pulmonary adverse events cited in clinical trials.

From: Association of cetuximab with adverse pulmonary events in cancer patients: a comprehensive review

  Colorectal Cancer Cetuximab Control Non-Small Cell Lung Cancer Cetuximab Control Head-Neck Cancer Cetuximab Control
  N (%) N (%) N (%) N (%) N (%) N (%)
Dyspnea/RI 70 (3.1) 35 (2.6) 131 (13.4) † 62 (9.2) 87 (8.7) † 26 (5.0)
PE 3 (0.1) 0 (0.0) 32 (3.3) 16 (2.4) 0 (0.0) 0 (0.0)
Pneumonia 2 (0.1) 0 (0.0) 4 (0.4) 1 (1.2) 13 (1.4) 4 (0.8)
ILD 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0)
Cough 0 (0.0) 0 (0.0) 8 (3.4) 3 (3.6) 42 (4.5) † 40 (7.8)
Pneumonitis 1 (0.0) 0 (0.0) 17 (1.7) † 0 (0.0) 0 (0.0) 0 (0.0)
Pleural Effusion 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 3 (0.3) 0 (0.0)
Increased Sputum 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 28 (3.0) † 34 (6.6)
TOTAL: 76 (3.4) 35 (2.6) 192 (19.6) † 82 (12.2) 173 (17.9) 104 (20.2)
  1. Patients were grouped into those who received cetuximab, either alone or in combination with other therapeutics, and controls (those who did not receive cetuximab). † p < 0.05 compared to control group.